Search research articles
Contact Us
Filters
Showing results (421-430 of 458) with videos related to
Page
of 46
Sort By:
JAMA Oncology
|
September 4, 2020
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, et al.
The Lancet. Oncology
|
September 30, 2021
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study
Juan W Valle, Arndt Vogel, Crystal S Denlinger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 28, 2012
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer
Manfred P Lutz, John R Zalcberg, Michel Ducreux, et al.
The New England Journal of Medicine
|
November 27, 2024
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer
Thierry Andre, Elena Elez, Eric Van Cutsem, et al.
The New England Journal of Medicine
|
June 2, 2025
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
Yelena Y Janjigian, Salah-Eddin Al-Batran, Zev A Wainberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 28, 2015
Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database
Lindsay A Renfro, Fotios Loupakis, Richard A Adams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen, Ken Kato, Sung-Bae Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2025
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study
Kohei Shitara, Sylvie Lorenzen, Jin Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2014
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database
Qian Shi, Aimery de Gramont, Axel Grothey, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 3, 2016
Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer
Manfred P Lutz, John R Zalcberg, Rob Glynne-Jones, et al.
Page
of 46
Search research articles
Search
Showing results (421-430 of 458) with videos related to
Sort By:
Page
of 46
JAMA Oncology
|
September 4, 2020
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, et al.
The Lancet. Oncology
|
September 30, 2021
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study
Juan W Valle, Arndt Vogel, Crystal S Denlinger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 28, 2012
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer
Manfred P Lutz, John R Zalcberg, Michel Ducreux, et al.
The New England Journal of Medicine
|
November 27, 2024
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer
Thierry Andre, Elena Elez, Eric Van Cutsem, et al.
The New England Journal of Medicine
|
June 2, 2025
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
Yelena Y Janjigian, Salah-Eddin Al-Batran, Zev A Wainberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 28, 2015
Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database
Lindsay A Renfro, Fotios Loupakis, Richard A Adams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen, Ken Kato, Sung-Bae Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2025
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study
Kohei Shitara, Sylvie Lorenzen, Jin Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2014
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database
Qian Shi, Aimery de Gramont, Axel Grothey, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 3, 2016
Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer
Manfred P Lutz, John R Zalcberg, Rob Glynne-Jones, et al.
Page
of 46